超早产儿解脲脲原体感染及定植状态的临床特征分析

doi:10.7499/j.issn.1008-8830.2403002

Abstract
Figure/Table
References(27)
Related Citation (15)
Read Tracking
Download Tracking

Download: PDF (598 KB) HTML
Export: BibTeX | EndNote (RIS) Supporting Info

Abstract Objective To investigate the clinical characteristics of Ureaplasma urealyticum (UU) infection and colonization in extremely preterm infants and its impact on the incidence of bronchopulmonary dysplasia (BPD). Methods A retrospective analysis was conducted on 258 extremely preterm infants who were admitted to the Department of Neonatology, Shenzhen Maternity and Child Healthcare Hospital, from September 2018 to September 2022. According to the results of UU nucleic acid testing and the evaluation criteria for UU infection and colonization, the subjects were divided into three groups: UU-negative group (155 infants), UU infection group (70 infants), and UU colonization group (33 infants). The three groups were compared in terms of general information and primary and secondary clinical outcomes. Results Compared with the UU-negative group, the UU infection group had significant increases in the incidence rate of BPD, total oxygen supply time, and the length of hospital stay (P<0.05), while there were no significant differences in the incidence rates of BPD and moderate/severe BPD between the UU colonization group and the UU-negative group (P>0.05). Conclusions The impact of UU on the incidence of BPD in extremely preterm infants is associated with the pathogenic state of UU (i.e., infection or colonization), and there are significant increases in the incidence rate of BPD, total oxygen supply time, and the length of hospital stay in extremely preterm infants with UU infection. UU colonization is not associated with the incidence of BPD and moderate/severe BPD in extremely preterm infants.

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Yan-Qiong
	ZENG Ya-Li
	CHEN Xue-Yu
	HUANG Zhi-Feng
	YANG Chuan-Zhong

Key words： Ureaplasma urealyticum Infection Colonization Clinical charateristic Extremely preterm infant

Received: 04 March 2024

Corresponding Authors: Yang C-Z，E-mail：yangczgd@163.com E-mail: yangczgd@163.com

Cite this article:

WANG Yan-Qiong,ZENG Ya-Li,CHEN Xue-Yu et al. Clinical characteristics of Ureaplasma urealyticum infection and colonization in extremely preterm infants[J]. CJCP, 2024, 26(8): 811-816.

URL:

http://www.zgddek.com/EN/10.7499/j.issn.1008-8830.2403002 OR http://www.zgddek.com/EN/Y2024/V26/I8/811

	Strauss M, Colodner R, Sagas D, et al. Detection of Ureaplasma species by a semi-quantitative PCR test in urine samples: can it predict clinical significance?[J]. Isr Med Assoc J, 2018, 20(1): 9-13. PMID: 29658200.
	Abele-Horn M, Peters J, Genzel-Boroviczény O, et al. Vaginal Ureaplasma urealyticum colonization: influence on pregnancy outcome and neonatal morbidity[J]. Infection, 1997, 25(5): 286-291. PMID: 9334863. DOI: 10.1007/BF01720398.
	Kafetzis DA, Skevaki CL, Skouteri V, et al. Maternal genital colonization with Ureaplasma urealyticum promotes preterm delivery: association of the respiratory colonization of premature infants with chronic lung disease and increased mortality[J]. Clin Infect Dis, 2004, 39(8): 1113-1122. PMID: 15486833. DOI: 10.1086/424505.
	Heggie AD, Bar-Shain D, Boxerbaum B, et al. Identification and quantification of Ureaplasmas colonizing the respiratory tract and assessment of their role in the development of chronic lung disease in preterm infants[J]. Pediatr Infect Dis J, 2001, 20(9): 854-859. PMID: 11734763. DOI: 10.1097/00006454-200109000-00006.
	Resch B, Gutmann C, Reiterer F, et al. Neonatal Ureaplasma urealyticum colonization increases pulmonary and cerebral morbidity despite treatment with macrolide antibiotics[J]. Infection, 2016, 44(3): 323-327. PMID: 26518581. DOI: 10.1007/s15010-015-0858-7.
	Vallely LM, Egli-Gany D, Pomat W, et al. Adverse pregnancy and neonatal outcomes associated with Neisseria gonorrhoeae, Mycoplasma genitalium, M. hominis, Ureaplasma urealyticum and U. parvum: a systematic review and meta-analysis protocol[J]. BMJ Open, 2018, 8(11): e024175. PMID: 30498048. PMCID: PMC6278811. DOI: 10.1136/bmjopen-2018-024175.
	Viscardi RM, Hasday JD. Role of Ureaplasma species in neonatal chronic lung disease: epidemiologic and experimental evidence[J]. Pediatr Res, 2009, 65(5 Pt 2): 84R-90R. PMID: 19190528. PMCID: PMC2920621. DOI: 10.1203/PDR.0b013e31819dc2f9.
	Moreira A, Benvenuto D, Fox-Good C, et al. Development and validation of a mortality prediction model in extremely low gestational age neonates[J]. Neonatology, 2022, 119(4): 418-427. PMID: 35598593. PMCID: PMC9296601. DOI: 10.1159/000524729.
	Chen X, Huang X, Lin Y, et al. Association of Ureaplasma infection pattern and azithromycin treatment effect with bronchopulmonary dysplasia in Ureaplasma positive infants: a cohort study[J]. BMC Pulm Med, 2023, 23(1): 229. PMID: 37365524. PMCID: PMC10294412. DOI: 10.1186/s12890-023-02522-4.
	Ballard HO, Anstead MI, Shook LA. Azithromycin in the extremely low birth weight infant for the prevention of bronchopulmonary dysplasia: a pilot study[J]. Respir Res, 2007, 8(1): 41. PMID: 17550598. PMCID: PMC1896160. DOI: 10.1186/1465-9921-8-41.
	11 中华中医药学会儿童肺炎联盟. 儿童肺炎支原体肺炎中西医结合诊治专家共识（2017年制定）[J]. 中国实用儿科杂志, 2017, 32(12): 881-885. DOI: 10.19538/j.ek2017120601.
	Higgins RD, Jobe AH, Koso-Thomas M, et al. Bronchopulmonary dysplasia: executive summary of a workshop[J]. J Pediatr, 2018, 197: 300-308. PMID: 29551318. PMCID: PMC5970962. DOI: 10.1016/j.jpeds.2018.01.043.
	Clyman RI, Liebowitz M, Kaempf J, et al. PDA-TOLERATE trial: an exploratory randomized controlled trial of treatment of moderate-to-large patent ductus arteriosus at 1 week of age[J]. J Pediatr, 2019, 205: 41-48.e6. PMID: 30340932. PMCID: PMC6502709. DOI: 10.1016/j.jpeds.2018.09.012.
	Hamrick SEG, Sallmon H, Rose AT, et al. Patent ductus arteriosus of the preterm infant[J]. Pediatrics, 2020, 146(5): e20201209. PMID: 33093140. PMCID: PMC7605084. DOI: 10.1542/peds.2020-1209.
	15 邵肖梅, 叶鸿瑁, 丘小汕. 实用新生儿学[M]. 5版. 北京: 人民卫生出版社, 2019.
	鲍毓, 赵正言, 施丽萍, 等. 解脲脲原体感染在早产儿支气管肺发育不良中的临床意义[J]. 中华儿科杂志, 2012, 50(10): 767-770. PMID: 23302568. DOI: 10.3760/cma.j.issn.0578-1310.2012.10.014.
	Viscardi RM, Kallapur SG. Role of Ureaplasma respiratory tract colonization in bronchopulmonary dysplasia pathogenesis: current concepts and update[J]. Clin Perinatol, 2015, 42(4): 719-738. PMID: 26593075. PMCID: PMC4662049. DOI: 10.1016/j.clp.2015.08.003.
	Lowe J, Watkins WJ, Edwards MO, et al. Association between pulmonary Ureaplasma colonization and bronchopulmonary dysplasia in preterm infants: updated systematic review and meta-analysis[J]. Pediatr Infect Dis J, 2014, 33(7): 697-702. PMID: 24445836. DOI: 10.1097/INF.0000000000000239.
	Nunes CR, Procianoy RS, Corso AL, et al. Use of azithromycin for the prevention of lung injury in mechanically ventilated preterm neonates: a randomized controlled trial[J]. Neonatology, 2020, 117(4): 522-528. PMID: 32894857. DOI: 10.1159/000509462.
	Iliodromiti Z, Zygouris D, Sifakis S, et al. Acute lung injury in preterm fetuses and neonates: mechanisms and molecular pathways[J]. J Matern Fetal Neonatal Med, 2013, 26(17): 1696-1704. PMID: 23611524. DOI: 10.3109/14767058.2013.798284.
	Jung E, Romero R, Yeo L, et al. The fetal inflammatory response syndrome: the origins of a concept, pathophysiology, diagnosis, and obstetrical implications[J]. Semin Fetal Neonatal Med, 2020, 25(4): 101146. PMID: 33164775. PMCID: PMC10580248. DOI: 10.1016/j.siny.2020.101146.
	Viscardi RM, Terrin ML, Magder LS, et al. Randomised trial of azithromycin to eradicate Ureaplasma in preterm infants[J]. Arch Dis Child Fetal Neonatal Ed, 2020, 105(6): 615-622. PMID: 32170033. PMCID: PMC7592356. DOI: 10.1136/archdischild-2019-318122.
	Chang E, Ballard KE, Johnson PN, et al. Azithromycin for eradication of Ureaplasma and prevention of bronchopulmonary dysplasia in preterm neonates in the neonatal intensive care unit[J]. J Pediatr Pharmacol Ther, 2023, 28(1): 10-19. PMID: 36777984. PMCID: PMC9901312. DOI: 10.5863/1551-6776-28.1.10.
	魏红玲, 邢燕, 周颖, 等. 胎龄小于32周早产儿解脲脲原体肺炎的临床特征分析[J]. 中华预防医学杂志, 2021, 55(2): 239-244. PMID: 34645186. DOI: 10.3760/cma.j.cn112150-20201208-01432.
	Fan W, Wang Q, Liang Z, et al. Efficacy of azithromycin in treating Ureaplasma urealyticum: a systematic review and meta-analysis[J]. BMC Infect Dis, 2023, 23(1): 163. PMID: 36927441. PMCID: PMC10021952. DOI: 10.1186/s12879-023-08102-5.
	Cramer CL, Patterson A, Alchakaki A, et al. Immunomodulatory indications of azithromycin in respiratory disease: a concise review for the clinician[J]. Postgrad Med, 2017, 129(5): 493-499. PMID: 28116959. DOI: 10.1080/00325481.2017.1285677.
	P?usa T. Azithromycin in the treatment of patients with exacerbation of chronic obstructive pulmonary disease[J]. Pol Merkur Lekarski, 2020, 48(283): 65-68. PMID: 32218410.